Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Search Results for: six human multiple embryo
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis – Science Advances
Posted: Published on August 23rd, 2020
INTRODUCTION Targeted therapy represents a powerful strategy to treat hormone receptors (estrogen and progesterone) or human epidermal growth factor receptor 2 (HER2)positive breast cancers. However, for triple-negative breast cancer (TNBC), a particularly aggressive and heterogeneous disease, there are no effective targeted therapies and no precision therapeutic options (1, 2). Numerous studies suggest that targeting of specific signaling pathway or epigenetic mechanisms using monotherapeutic agents is not effective, whereas combination therapies of two or more molecular targets substantially improve clinical outcome Continue reading
Posted in HGH
Comments Off on Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis – Science Advances
Merck’s KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With…
Posted: Published on August 21st, 2020
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy (cisplatin plus 5-fluorouracil [5-FU]), met its primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with locally advanced or metastatic esophageal cancer. Based on an interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS and PFS compared with chemotherapy (cisplatin plus 5-FU), the current standard of care, in the intention-to-treat (ITT) population Continue reading
Posted in Hormone Replacement Therapy
Comments Off on Merck’s KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With…
Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency – Science Advances
Posted: Published on August 14th, 2020
INTRODUCTION Combination antiretroviral therapy (cART) causes a drastic and immediate viral decrease by targeting distinct steps in the HIV-1 life cycle, effectively blocking replication and halting disease progression (13). However, cART does not target or eliminate HIV that persists in a latent state in cellular reservoirs. Continue reading
Posted in MS Treatment
Comments Off on Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency – Science Advances
High-throughput 3D screening for differentiation of hPSC-derived cell therapy candidates – Science Advances
Posted: Published on August 10th, 2020
Abstract The emergence of several cell therapy candidates in the clinic is an encouraging sign for human diseases/disorders that currently have no effective treatment; however, scalable production of these cell therapies has become a bottleneck. To overcome this barrier, three-dimensional (3D) cell culture strategies have been considered for enhanced cell production Continue reading
Posted in Spinal Cord Injury Treatment
Comments Off on High-throughput 3D screening for differentiation of hPSC-derived cell therapy candidates – Science Advances
Synaptic zinc inhibition of NMDA receptors depends on the association of GluN2A with the zinc transporter ZnT1 – Science Advances
Posted: Published on July 4th, 2020
INTRODUCTION Zinc is a neuromodulator that regulates glutamatergic, -aminobutyric acidmediated (GABAergic), and glycinergic synaptic transmission (17); short- and long-term synaptic plasticity (2, 812); auditory processing; and acuity for sensory stimulus discrimination (1315). The zinc transporter ZnT3 (Slc30a3) packages zinc into presynaptic vesicles of large populations of excitatory neurons in many brain regions, including the cerebral cortex, hippocampus, amygdala, and dorsal cochlear nucleus (DCN) (16). During synaptic activity, vesicular zinc is released from ZnT3-containing terminals (1, 17) and diffuses across the synaptic cleft (4) to modulate a number of postsynaptic receptors (3, 6, 18, 19), including the highly zinc-sensitive N-methyl-d-aspartate receptor (NMDAR) (2, 4, 20). Continue reading
Posted in MS Treatment
Comments Off on Synaptic zinc inhibition of NMDA receptors depends on the association of GluN2A with the zinc transporter ZnT1 – Science Advances
FDA Approves Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that…
Posted: Published on June 24th, 2020
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Continue reading
Posted in Hormone Replacement Therapy
Comments Off on FDA Approves Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that…
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients…
Posted: Published on June 13th, 2020
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-361 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy. In the final analysis of the study, there was an improvement in OS and PFS for patients treated with KEYTRUDA in combination with chemotherapy (cisplatin or carboplatin plus gemcitabine) compared to chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan Continue reading
Posted in Hormone Replacement Therapy
Comments Off on Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients…
Lilly Receives U.S. FDA Approval for Retevmo(TM) (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and…
Posted: Published on May 9th, 2020
INDIANAPOLIS, May 8, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA)approved Retevmo (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC),and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Continue reading
Posted in Myocardial Infarction
Comments Off on Lilly Receives U.S. FDA Approval for Retevmo(TM) (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and…
Left Ventricular Remodelling – ECR Journal
Posted: Published on April 23rd, 2020
The term cardiac remodelling (REM) is used to define changes that produce geometrical rearrangement of the normal structures of the heart, together with complex biological and molecular alterations. REM affects the heart at the level of the cardiomyocyte, the blood vessels and the extracellular matrix. Continue reading
Posted in Ventricular Remodeling
Comments Off on Left Ventricular Remodelling – ECR Journal
Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity – Science Advances
Posted: Published on February 1st, 2020
INTRODUCTION Anthracycline is a group of chemotherapeutic drugs that are being actively used to treat broad types of cancer (1, 2), but the major clinical complication for these antibiotics is their dose-dependent cardiotoxicity (1). Several mechanisms have been proposed for anthracycline-induced cardiotoxicity (AIC), including topoisomerase II (coded by TOP2B) as a primary mediator (3). On the basis of these mechanisms, dexrazoxane, an iron chelator, has been successfully developed as the only U.S Continue reading
Posted in Ventricular Remodeling
Comments Off on Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity – Science Advances